Stock abbreviation: Sichuan Kelun Pharmaceutical Co.Ltd(002422) Stock Code: Sichuan Kelun Pharmaceutical Co.Ltd(002422) Sichuan Kelun Pharmaceutical Co.Ltd(002422)
Sichuan Kelun Pharmaceutical Co., Ltd.
(address: NanEr Road, Industrial Development Zone, Xindu satellite city, Chengdu)
Public issuance of convertible corporate bonds
Prospectus
Sponsor / lead underwriter / trustee
(address: 28th floor, No. 1198, Century Avenue, China (Shanghai) pilot Free Trade Zone)
Signed on:
Statement
All directors, supervisors and senior managers of the company promise that the prospectus and its abstract do not contain any false, misleading statements or major omissions, and guarantee the authenticity, accuracy and completeness of the information disclosed.
The person in charge of the company, the person in charge of accounting and the person in charge of the accounting organization (Accounting Supervisor) shall ensure that the financial and accounting reports in the prospectus and its abstract are true and complete.
Any decision made by the securities regulatory authority and other government departments on this issuance does not indicate that they have made a substantive judgment or guarantee on the value of the securities issued by the company or the income of investors. Any statement to the contrary is a false statement.
According to the provisions of the securities law, after the securities are issued according to law, the company shall be responsible for the changes in the company’s operation and income, and the investors shall be responsible for the investment risks caused by the changes.
Tips on major issues
When evaluating the convertible corporate bonds issued this time, investors should pay special attention to the following major matters and carefully read the chapter on risk factors in this prospectus. 1、 Notes on the issuance of convertible bonds meeting the issuance conditions
According to the securities law, the measures for the administration of securities issuance of listed companies and other relevant regulations, the company’s public issuance of convertible corporate bonds meets the statutory issuance conditions. 2、 On the credit rating of convertible bonds issued this time
China integrity international has carried out credit rating on the convertible corporate bonds issued this time and made corresponding arrangements for follow-up rating. According to the credit rating report of Sichuan Kelun Pharmaceutical Co.Ltd(002422) public issuance of convertible corporate bonds issued by zhongchengxin international, the main credit rating of the company is AA +, the rating prospect is stable, and the credit rating of this bond is AA +.
During the validity period of the credit rating of this rating (until the agreed repayment date of the principal and interest of this bond), China integrity international will conduct tracking rating at least once a year. If the credit rating of the convertible bonds is lowered due to factors such as the external business environment, the company’s own situation or the change of rating standards, it will increase the investment risk of investors and have a certain impact on the interests of investors. 3、 Profit distribution policy of the company and profit distribution in recent three years
For the dividend distribution policy and decision-making mechanism of the company, please refer to “XIV. Dividend distribution of the company” in “section IV basic information of the issuer” of this prospectus. 4、 Cash dividends of the company in recent three years
